Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: TECOS: A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Sitagliptin in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control
Brief Summary: This is a clinical trial designed to assess the cardiovascular outcome of long-term treatment with sitagliptin used as part of usual care compared to usual care without sitagliptin in participants with type 2 diabetes mellitus (T2DM) having a history of cardiovascular (CV) disease and a hemoglobin A1c (HbA1c) of 6.5% to 8.0%.

Primary hypothesis A is that sitagliptin, when used as part of usual care, is non-inferior to usual care without sitagliptin with regard to the risk of developing a confirmed event in the primary CV composite endpoint of Major Adverse Cardiovascular Event (MACE) plus. If hypothesis A is satisfied: hypothesis B is that sitagliptin, when used as part of usual care, is superior to usual care without sitagliptin with regard to the risk of developing a confirmed event in the primary CV composite endpoint.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: dapagliflozin, Drug: Glimepiride, Drug: metformin hydrochloride, Drug: pioglitazone hydrochloride, Drug: Rosiglitazone | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: dapagliflozin, Drug: Glimepiride, Drug: metformin hydrochloride, Drug: pioglitazone hydrochloride, Drug: Rosiglitazone | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: dapagliflozin, Drug: Glimepiride, Drug: metformin hydrochloride, Drug: pioglitazone hydrochloride, Drug: Rosiglitazone | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Glimepiride, Drug: metformin hydrochloride, Drug: pioglitazone hydrochloride, Drug: Rosiglitazone | Intervention Type: DRUG; Name: dapagliflozin; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: metformin hydrochloride; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: pioglitazone hydrochloride; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): 1, 2, 3, 4
B: Arm Label: 0.5 units/kg; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.5 units/kg daily insulin | Arm Label: 0.25 units/kg; Type: EXPERIMENTAL; Interventions: Drug: 0.25 units/kg daily insulin | Intervention Type: DRUG; Name: 0.5 units/kg daily insulin; Assigned to Arm(s): 0.5 units/kg | Intervention Type: DRUG; Name: 0.25 units/kg daily insulin; Assigned to Arm(s): 0.25 units/kg
C: Arm Label: 001; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin 300mg/Placebo | Arm Label: 003; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin 300mg | Arm Label: 004; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin 300mg/Canagliflozin 150mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: Canagliflozin 300mg/Placebo; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Canagliflozin 300mg/Canagliflozin 150mg; Assigned to Arm(s): 004 | Intervention Type: DRUG; Name: Canagliflozin 300mg; Assigned to Arm(s): 003
D: Arm Label: Sitagliptin; Type: EXPERIMENTAL; Interventions: Drug: Sitagliptin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sitagliptin; Assigned to Arm(s): Sitagliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D